YKL-40 in giant cells and macrophages from patients with giant cell arteritis

J S Johansen1, B Baslund, C Garbarsch

  • 1Department of Rheumatology, Hvidovre Hospital, Denmark.

Arthritis and Rheumatism
|January 1, 2000
PubMed

Insights

Giant cell arteritis (GCA) patients show elevated YKL-40 in serum and inflamed arteries. YKL-40 levels in GCA patients decrease with prednisolone treatment, indicating its role in disease activity.

Area of Science:

  • Biochemistry
  • Immunology
  • Rheumatology

Background:

  • YKL-40 is a mammalian chitinase-like enzyme secreted by activated macrophages.
  • Macrophages and giant cells are implicated in the pathogenesis of giant cell arteritis (GCA).

Purpose of the Study:

  • To investigate YKL-40 production by macrophages and giant cells in GCA patients.
  • To determine if serum YKL-40 levels are elevated in GCA patients.

Main Methods:

  • Immunohistochemical staining for YKL-40 in temporal artery biopsies from GCA patients.
  • Serum YKL-40 levels measured by radioimmunoassay in GCA and polymyalgia rheumatica (PMR) patients during prednisolone treatment.

Main Results:

  • YKL-40 was detected in CD68+ giant cells and mononuclear cells within the media of arteritic vessels in GCA patients.
  • GCA patients exhibited significantly higher median serum YKL-40 levels (256 microg/L) compared to healthy controls (118 microg/L).
  • Serum YKL-40 levels decreased by 38% after 1 month of prednisolone treatment in GCA patients, returning to normal levels.

Conclusions:

  • YKL-40 is present in macrophages and giant cells within the inflamed arteries of GCA patients.
  • Serum YKL-40 concentration may serve as a biomarker for the local inflammatory activity in GCA.
Abstract